Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court ...

If you haven't already heard the news, Prime Video's House of David has been put on the map as one of the streamer's biggest recent hits, earning it a quick Season 2 renewal. The show's quick ...

Regeneron Pharmaceuticals recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing serious ...

San Francisco, California--(Newsfile Corp. - March 3, 2025) - Biotechnology giant Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is embroiled in a securities class action lawsuit, alleging the ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc (NASDAQ:REGN) stands against other stocks that Jim Cramer discusses. Jim Cramer in a recent program on CNBC ...

The story of David and Goliath is so well known it’s a shorthand for any smaller force taking on a larger one. David and Batsheva’s affair is commemorated in Leonard Cohen’s “Hallelujah.” ...

"House of David" pumps up the greatest Bible battle of them all: David vs. Goliath. The Amazon Prime series (first three episodes now streaming, then weekly on Thursdays) tells the origin tale of ...

“House of David” tells the coming-of-age story of the Biblical hero, who took down the giant Goliath with a simple slingshot and later became King of Israel. Newcomer Michael Iskander stars in ...

This week, streaming service Prime Video debuts “House of David,” a show that’s a prequel of sorts to “The Chosen” while being largely unaffiliated. (“The Chosen” is spearheaded by ...

Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best biotech stocks. Although biotech stocks had a “challenging” year ...

11:09 EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fight Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed ...